Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2014 07:30 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Year-End 2014 Update and 2015 Plans to Advance Its Clinical Pipeline and Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)

SAN DIEGO, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reviewed its 2014...
December 15, 2014 07:30 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer

SAN DIEGO, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
December 04, 2014 07:30 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in Patients With Raynaud's Phenomenon

SAN DIEGO, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
December 02, 2014 07:30 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer

SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
November 10, 2014 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update

Company Recently Expanded Development Pipeline with U.S. In-License of Fispemifene Vitaros® Launch Continues to Exhibit Strength in Europe Conference Call and Webcast Today, Monday,...
November 05, 2014 07:30 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences to Present at Three Upcoming Investor Conferences in November and December of 2014

SAN DIEGO, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a developer of biopharmaceutical therapeutics for urology and rheumatology disorders, today announced that members...
November 04, 2014 07:30 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Corporate Update and Third Quarter 2014 Financial Results Conference Call

SAN DIEGO, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the...
November 03, 2014 06:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Belgium by Sandoz

SAN DIEGO, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced the...
October 20, 2014 02:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Expands Development Pipeline With the In-Licensing of U.S. Rights for Fispemifene, a Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions in Men

-- Apricus Funds Upfront License Fee and 2015 Phase 2b Development Cost with $10 Million Venture Debt Financing -- --Conference Call Today, Monday, Oct. 20, at 8:00 a.m. ET-- SAN DIEGO, Oct. 20,...
October 13, 2014 07:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa(TM)

SAN DIEGO, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the...